Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. 1992

T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
Department of Surgery II, Osaka University Medical School, Japan.

BACKGROUND An optimal treatment schedule of 5-fluorouracil (5-FU) remains to be clarified. METHODS A randomized study was conducted to investigate schedule-dependent thymidylate synthase (TS) inhibition by 5-FU in 16 patients with gastric cancer who underwent surgical resection. Surgical specimens of tumor, normal gastric mucosa, and regional lymph nodes were obtained 12 hours after administration of 5-FU either as a continuous infusion (1000 mg/m2 for 48 hours) or as a bolus injection (500 mg/m2 x 2 in 48 hours). RESULTS The total TS activity (567.8 +/- 294 fmol/mg protein) and the rate of TS inhibition (74.7 +/- 23.1%) in cancer tissues were significantly higher in the continuous-infusion group than in the bolus-injection group (228.5 +/- 104.6 fmol/mg protein and 48.8 +/- 12%, respectively). Likewise, the total TS activity (807.4 +/- 440.3 fmol/mg protein) and the rates of TS inhibition in lymph nodes (72.3 +/- 17.1%) and in normal gastric mucosa (85.1 +/- 12.2%) were significantly higher in the continuous-infusion group than those in the bolus-injection group (232.4 +/- 142.3 fmol/mg protein and 53.6 +/- 17.0% in lymph nodes and 46.5 +/- 14.3% in normal gastric mucosa, respectively). There was a significant correlation between the total TS activity and TS inhibition. CONCLUSIONS Continuous infusion of 5-FU provides a superior antimetabolic effect in the treatment of gastric cancer, which may lead to a superior antitumor effect.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005468 Fluorodeoxyuridylate 5-Fluoro-2'-deoxyuridylate. An inhibitor of thymidylate synthetase. Formed from 5-fluorouracil or 5-fluorodeoxyuridine. 5-Fluoro-2'-Deoxyuridine-5'-Monophosphate,FdUMP,5 Fluoro 2' Deoxyuridine 5' Monophosphate

Related Publications

T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
January 1989, Advances in experimental medicine and biology,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
January 2014, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
January 1993, Advances in experimental medicine and biology,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
January 1993, Anticancer research,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
October 1988, Cancer research,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
August 2001, International journal of oncology,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
January 1991, Advances in experimental medicine and biology,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
December 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
March 1984, Molecular pharmacology,
T Tsujinaka, and Y Kido, and H Shiozaki, and S Iijima, and T Homma, and M Sakaue, and T Mori
February 2015, Oncology reports,
Copied contents to your clipboard!